B+
Bull case
25%
Probability
Target price
$24.00
+75.7% vs current
VOR
Vor BiopharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$15.00
+9.8% vs current
B-
Bear case
30%
Probability
Target price
$9.00
-34.1% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
-0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+62.1
Score
AI commentary
Sentiment is mixed-to-cautious rather than outright bullish. The company-source Q1 release on May 13, 2026 was operationally supportive, but independent earnings trackers reported only a modest EPS beat and an immediate negative stock reaction of roughly 3.4% the following day. As of May 16, 2026, no trustworthy post-print analyst target or rating revision signal was confirmed, so this remains a monitoring-style thesis rather than a high-conviction re-rating call.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystPost-earnings digestion centers on runway and cleaner operating read-throughHigh impact
The May 13, 2026 Q1 update confirmed $491.5 million of cash, cash equivalents and marketable securities as of March 31, 2026 and runway into early 2029, while the quarter’s large GAAP net loss was driven mainly by warrant-liability fair value changes rather than core operating deterioration. Near-term trading likely depends on whether investors re-rate the stock around the cash runway and Phase 3 focus after the initial post-print pullback [#10-Q-2026-05-13].
2026-12-31eventUPSTREAM SjD enrollment progress is the next program-execution checkpointHigh impact
The company disclosed that it recently initiated the global Phase 3 SjD study, with first patient dosing in March 2026 and planned recruitment of about 250 adults across the U.S., Europe, South America and Asia. Additional evidence that sites and enrollment are progressing would support the thesis that Vor can execute two late-stage autoimmune programs with its current balance sheet [#10-K-2026-03-30].
2027-06-30catalystUPSTREAM MG Phase 3 topline remains the main value driverHigh impact
Vor said enrollment is ongoing in the global randomized Phase 3 UPSTREAM MG trial and that topline data are anticipated in 1H27. Because VOR is now largely a telitacicept-driven story, meaningful de-risking on enrollment or eventual topline efficacy and safety can have an outsized valuation impact [#10-Q-2026-05-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology